Michael Wang: CDK9 is a promising target in MCL

Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center shared a post on X about a recent paper by Vivian Jiang et al. titled “The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma” published in NIH.

Authors: Vivian Jiang, William Lee, Tianci Zhang, Alexa Jordan, Fangfang Yan, Qingsong Cai, Joseph McIntosh, Jovanny Vargas, Yang Liu, and Michael Wang.

Michael Wang commented on X, sharing the paper:

“Our newly published work shows Enitociclib leads to CDK9 inhibition and reduces levels of c-MYC, MCL-1, and cyclin D1, resulting in enhanced apoptosis and suppressed tumor growth. These data demonstrate that CDK9 is a promising target in MCL.”

Christopher Melani shared this post, adding:

“We are studying this drug in combination with venetoclax and prednisone in patients with R/R DLBCL and HGBCL-DH-BCL2. If safe, may be wise to expand in R/R MCL as well.”                                 .

Sources: Michael Wang/X and Christopher Melani/X